Member Info for Benhowell459

6th April, Colin told the roast chaps that it was 3-4 weeks before concentration feasibility study would be ready. Almost 8 weeks later and not a zip. Either Colin is sitting on it and plugging in the numbers or his forward looking statements are once again about as useful as a chocolate teapot. Old habits die hard.

I completely agree with the previous comments. I hope with all my being that Colin appreciates that he alone is responsible for the hyperboles RE size of BR, irresponsible statements in interviews with Zac and the Roast boys RE timescales.

Shareholders now know they simply cannot trust any of his forward guidance. ("Bow on it by April 2022", "I'm not worried about grades"). The wider AIM market investors have cottoned on to his shenanigans - part truths, exaggerations - and are staring clear.

I am disappointed I won't be able to make the AGM - I sincerely hope there will be a whole bunch of LTHs who can give him both barrels. We have had almost zero visible progress with BR since the last AGM and the ultimate weather vane, the share price has plummeted. On your head be it, Mr Bird. Pull your finger out and sort out this mess - either by stepping aside (you evidently have not got what it takes) or being honest with us all.

*Small caveat: the above can be ignored if we sell for 10p in the period for the AGM. Unlikely but Colin might be dreading what's coming at the AGM...

Colin's favourite day for an RNS tomorrow. Wakey wakey, Colin. Let's be 'avng you!

Agree captain, would be nice if Colin remembered he had BR in the depths of his pockets...

Now the PL is very nearly over, he can stop tweeting about Nottingham Forest and focus on triggering that buy back clause!

If the crowd are avoiding AIM due to it seeming a riskier area to invest, or simply due to economic downturn means PIs have less funds, how are we ever going to return to 6p?

The only two ways I can actually see shareholder value here are

A) a buy out.

B) dividends.

A is obviously preferable. I don't really want to be hanging around for the Kakuye to come to fruition and/or other random African copper adventures. I've been here 5 years and put up with enough of Colin's unrealistic timescales and over-exuberance. Problem is - will others want to buy us out like Kiwara when we have a whole stable of random projects alongside BR. Manica itself does not seem interesting enough to PIs, hence my concern anyone who bought at 6p+ won't see a return of their money, unless a buy out takes place.

Colin, you sold us the dream. Get this thing sold. Put a bow on it, like you said. I'll take 10p now, unlike you when you ridiculously rejected a hypothetical 10p bid.

Sounds about right from what I can remember of last August. Issue is we are once again approaching AGM time with no progress at BR in the last 9 months. The 789 lashes are starting to hurt, Colin...

So Highlightll received $10mn in cash, $10mn in equity and milestone payments of up to $950mn for a pre phase 1 TYK2/JAK1.

Presumably, if we pass phase 1 ourselves, it will prove safety and dwarf the numbers above, should we choose to on-licence 1801. Would rather we sell all in H2 of this year so speed up the wait time.

I have a question regarding competition. Some on here have claimed we are "first in class" as an orally taken TYK2 JAK1 dual inhibitor. This is not entirely accurate. Brepocitinib, owned by Priovant, is exactly that and has already been through 14 phase 1 and 2 trials, including 5 placebo controlled trials. (https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing)

One of these trials was conducted with Psoriasis patients back in 2020. Essentially we are 3 years behind this orally taken TYK2 JAK1. I think some of the claims become factually correct when the word "available" is added. I.e. We are the only available oral TYK2 JAK1. Essentially because Priovant aren't going to sell brepocitinib to anyone.

The crux of the matter, therefore, in my opinion, is the following. There is space for more than one TYK2 JAK1 inhibitor on the market. But given we are 3 years behind, what differentiates us from brepocitinib? I remember Thoth mentioning something about us attaching directly to the correct site. Does anyone have any detail on this?

For info, the trial relating to brepocitinib against psoriasis in 2020 (PF-06700841 is now called brepocitinib): https://pubmed.ncbi.nlm.nih.gov/31972249/

What is an absolute shame is that these sp predictions for our very own 100% owned compound reaching clinical trials are still nowhere near where we were after the HNWI investments.

£3 a share is 6p. Several bought in at 8p+, which is £4.

If SRA737 is onlicenced AND we have our very own compound, I would very much like to think we would be well over 9p, i.e. the last spike, and MC of over 300m.

Great find HBD - thanks very much for sharing!

I think the level of detail in that link (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385555&isReview=true) is very interesting.

We were always wondering what the top dose would be - do we have our answer?

The planned dose escalation sequence for SDC-1801/placebo in Part 1 is shown below:
Cohort A: starting dose = 5 mg
Cohort B: a dose not to exceed 10 mg
Cohort C: a dose not to exceed 30 mg
Cohort D: a dose not to exceed 75 mg
Cohort E: a dose not to exceed 150 mg
Cohort F: a dose not to exceed 300 mg.

We also have some idea of how long it will take to get results from the trial. There is an excellent amount of detail here which points to a highly positive response to our CTA.

It would appear 1801 is going into the clinic. What a lovely bit of news for a sunny BH weekend!

Interesting post howezap.

I think it also shows a few things:

1) There is an interest in moving into the copper sphere to get a piece of the action. Harmony are predominantly a gold producer. We heard that Barrick are also looking at copper. Things are definitely hotting up with big boys wanting in.

2) We are in a solid jurisdiction and miners will see that as an advantage. Barrick did mention Africa, but that's presumably because they are very active there already.

3) This is one less resource on the market. Eva is gone. The pool of mineable resources will shrink over the next few years as demand picks up.

4) Related to point 3, as demand picks up, the copper supply is shrinking. We are currently at the lowest LME warehouse inventory for a long long time. We could be in for a perfect storm whereby demand for takeovers picks up at the moment the supply side is severely constrained.

5) Eva and BR are completely different resources as you say. IOCGs require a huge amount of drilling to define the mineralisation. This is, I believe, why Eureka IOCG has not been drilled out (along with distance to port, water and power supply). So we can't compare our metres of drilling with theirs.

Having said the above, I do wish AA would just save us all a year or two and give us £100m for the 4 BR licences once we publish the next study. Would save us all a load of hassle and give them the chance to direct how they proceed with mine planning/infill drilling. BR will almost certainly be a mine. The world needs the copper and BR, in the copper-rich Lachlan Fold, evidently has an abundance of it! GLA and happy weekend.

How on earth are we down if those are 2x 195k buys?! Those are huge!

Someone must know something!

Interesting progression for Prometheus and insight into what could happen here if the SAR BOD hold out over the next 4-5 years against partnerships with 1801/2.

Prometheus was valued at around 1 billion dollars back in April '21. Share price was down at 45-50 dollars as recently as November/December '22. (Around 2bn dollars)

Then they had very positive phase 2 results:

Prometheus’ Phase 2 ARTEMIS-UC clinical trial was a 12-week, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of PRA023 in patients with moderate-to-severely active UC who have failed conventional or advanced therapy.

26.5% of patients on PRA023 reached the primary endpoint of clinical remission (per modified Mayo Score), compared to 1.5% on placebo, for a placebo-adjusted clinical remission rate of 25.0% on the primary endpoint.

This more than doubled the MC to around 5.4bn. Fast forward 4-5 months and they are being bought out for 10.8bn dollars, at a 75% premium.

So positive phase 1 results got them to 1-2bn dollars. Real ramp up post phase 2 positive results.

Very simple look at the history and figures - I'm sure others will have even more interesting and insightful comments/corrections.

https://www.bbc.co.uk/news/health-65252510

Absolutely not!

2p incoming! Bring on a nice sunny weekend, less than 50% down!

Interesting shipwreck. Their MC currently around 47 AUS dollars which is around 25m GBP.

So some room to grow for the snake. Hopefully we announce 1m ounces of gold + an overlay of mineable REE. The perfect combo...

It would be much easier to just invest in significantly undervalued Oriole. A $1m US investment/placing at say a much higher level of 0.2p gives exposure to more than just those licences and gives them 18% (ish) of the shares ($1m US out of a MC of 5M GBP.

It's a slightly strange way of doing it. Admittedly Bob may have insisted they can't do a placing. In which case, they could just buy shares in ORR.

Fair enough to those keeping their feet on the ground. Only natural when this share has burnt so many fingers.

However, interesting to consider the implications of this investment. 10% of the 5 central package licences are worth $1m according to an investor.

Extrapolate that and we have $10m for 100%.

That's around double our current MC, excluding value attributed to Senala, Fare and the other licences in Cameroon.

We are extraordinarily undervalued through a combination of poor market sentiment and funding concerns. The latter may well have been sorted (I did say Bob needed to prove his worth - looks like he's pulled his socks up), the former can is out of our control.

If this goes through, it will be very positive for us and by extension, the sp. GLA.

"Unless GSK look specifically they will have no idea about this research, The Chinese certainly will not have informed them."

If GSK would not have known, can we safely assume that CRUK and SAR would also not know?

Would it be worth contacting SAR to see if they are in the know?

Sounds about right, Andrew.

I imagine Dani will still be waiting for it to ramp up to £1m a month net in Q3 2035. By then we'll all be long gone, having sold out in Q4 2023 at 15p when AA realised copper was going to the moon and made us an offer we couldn't refuse.

Dani refused to sell, explaining that Colin said in a podcast once in 2021 that we don't pay Operating costs in Mozambique. She was therefore waiting for "at least £1" before moving on. She ran the telegram group, after the Roast boys all cashed in their shares and sold out. The 2021 podcast link is pinned on the group.

The LSE site in 2035 is quiet, although interesting to note that one regular visitor from the 20s, Kwadoku, has changed his tune and argues that even he made some money from BR and XTR when it hit 15p. Steve4077 is an occasional visitor, popping in to claim he's made 20% on his copper trackers over the past 12 years.

Occasionally, retired Zak Mir loads a podcast on Vimeo with 92 year old Colin Bird, who brags about extending the strike at Kakuye to 280m and possibly doing some drills to test an IOCG at a place called Eureka. He recalls realising he had this licence stuffed at the bottom of his back pocket his "Eureka moment", as he'd forgotten he even had it. Zak says even less in the 2035 podcasts than he does now. Colin explains that drilling out Eureka will not be a "death by a thousand lashes" and will be in production by the end of the year 2035, to join the other 37 small ventures Xtract have signed up to in Zambia. Best place to look for elephants is where you've already found them, he jokes.

Have a good weekend all!